Efficacy of tiotropium in COPD patients from Asia

A subgroup analysis from the UPLIFT trial

Yoshinosuke Fukuchi, Lenora Fernandez, Han Pin Kuo, Aziah Mahayiddin, Bartolome Celli, Marc Decramer, Steven Kesten, Dacheng Liu, Donald Tashkin

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background and objective: Studies in respiratory diseases other than chronic obstructive pulmonary disease suggest potentially differing responses to medications among patients from different regions. We report a subgroup analysis of patients recruited to Asian centres from a previously reported 4-year COPD trial. Methods: Subgroup analysis from a randomized, double-blinded, placebo-controlled trial of tiotropium 18 μg daily in COPD. Primary end-point was rate of decline in FEV 1. Secondary end-points included spirometry at individual time points, health-related quality of life (St George's Respiratory Questionnaire), exacerbations and mortality. Results: Of 5992 patients, 362 were from Asian centres (100 from Japan). Mean age 66 years, 95% men, 13% current smokers, BMI: 21 kg/m 2; post-bronchodilator FEV 1: 44% predicted; St George's Respiratory Questionnaire total score: 44 units. No treatment effect was observed for rate of decline in FEV 1 although annual decline was less in Asian patients. Morning prebronchodilator FEV 1 and forced vital capacity improved in Asian patients (P < 0.05). Tiotropium reduced number of exacerbations (rate ratio (95% confidence interval (CI)): 0.73 (0.57-0.94)). Hazard ratios (95%CI) for exacerbations and hospitalized exacerbations (tiotropium/control) were 0.81 (0.62-1.05) and 0.85 (0.61-1.19), respectively. St George's Respiratory Questionnaire total score improvedby 1.5-6.1 units (P < 0.05 for months 18, 24, 30 and 36) with tiotropium. Fatal events occurred in 34 tiotropium (18.5%) and 42 control (23.6%) patients. Conclusions: In COPD patients from Asia, tiotropium improves lung function, improves health-related quality of life and reduces exacerbations over 4 years of treatment.

Original languageEnglish
Pages (from-to)825-835
Number of pages11
JournalRespirology
Volume16
Issue number5
DOIs
Publication statusPublished - Jul 1 2011
Externally publishedYes

Fingerprint

Chronic Obstructive Pulmonary Disease
Quality of Life
Confidence Intervals
Bronchodilator Agents
Spirometry
Vital Capacity
Tiotropium Bromide
Japan
Placebos
Lung
Mortality
Therapeutics
Surveys and Questionnaires

Keywords

  • Asia
  • Chronic obstructive pulmonary disease
  • Quality of life
  • Spirometry
  • Tiotropium

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Fukuchi, Y., Fernandez, L., Kuo, H. P., Mahayiddin, A., Celli, B., Decramer, M., ... Tashkin, D. (2011). Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology, 16(5), 825-835. https://doi.org/10.1111/j.1440-1843.2011.01982.x

Efficacy of tiotropium in COPD patients from Asia : A subgroup analysis from the UPLIFT trial. / Fukuchi, Yoshinosuke; Fernandez, Lenora; Kuo, Han Pin; Mahayiddin, Aziah; Celli, Bartolome; Decramer, Marc; Kesten, Steven; Liu, Dacheng; Tashkin, Donald.

In: Respirology, Vol. 16, No. 5, 01.07.2011, p. 825-835.

Research output: Contribution to journalArticle

Fukuchi, Y, Fernandez, L, Kuo, HP, Mahayiddin, A, Celli, B, Decramer, M, Kesten, S, Liu, D & Tashkin, D 2011, 'Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial', Respirology, vol. 16, no. 5, pp. 825-835. https://doi.org/10.1111/j.1440-1843.2011.01982.x
Fukuchi, Yoshinosuke ; Fernandez, Lenora ; Kuo, Han Pin ; Mahayiddin, Aziah ; Celli, Bartolome ; Decramer, Marc ; Kesten, Steven ; Liu, Dacheng ; Tashkin, Donald. / Efficacy of tiotropium in COPD patients from Asia : A subgroup analysis from the UPLIFT trial. In: Respirology. 2011 ; Vol. 16, No. 5. pp. 825-835.
@article{cc5f8e0d8f424f9dbdd76a74da6c8f2f,
title = "Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial",
abstract = "Background and objective: Studies in respiratory diseases other than chronic obstructive pulmonary disease suggest potentially differing responses to medications among patients from different regions. We report a subgroup analysis of patients recruited to Asian centres from a previously reported 4-year COPD trial. Methods: Subgroup analysis from a randomized, double-blinded, placebo-controlled trial of tiotropium 18 μg daily in COPD. Primary end-point was rate of decline in FEV 1. Secondary end-points included spirometry at individual time points, health-related quality of life (St George's Respiratory Questionnaire), exacerbations and mortality. Results: Of 5992 patients, 362 were from Asian centres (100 from Japan). Mean age 66 years, 95{\%} men, 13{\%} current smokers, BMI: 21 kg/m 2; post-bronchodilator FEV 1: 44{\%} predicted; St George's Respiratory Questionnaire total score: 44 units. No treatment effect was observed for rate of decline in FEV 1 although annual decline was less in Asian patients. Morning prebronchodilator FEV 1 and forced vital capacity improved in Asian patients (P < 0.05). Tiotropium reduced number of exacerbations (rate ratio (95{\%} confidence interval (CI)): 0.73 (0.57-0.94)). Hazard ratios (95{\%}CI) for exacerbations and hospitalized exacerbations (tiotropium/control) were 0.81 (0.62-1.05) and 0.85 (0.61-1.19), respectively. St George's Respiratory Questionnaire total score improvedby 1.5-6.1 units (P < 0.05 for months 18, 24, 30 and 36) with tiotropium. Fatal events occurred in 34 tiotropium (18.5{\%}) and 42 control (23.6{\%}) patients. Conclusions: In COPD patients from Asia, tiotropium improves lung function, improves health-related quality of life and reduces exacerbations over 4 years of treatment.",
keywords = "Asia, Chronic obstructive pulmonary disease, Quality of life, Spirometry, Tiotropium",
author = "Yoshinosuke Fukuchi and Lenora Fernandez and Kuo, {Han Pin} and Aziah Mahayiddin and Bartolome Celli and Marc Decramer and Steven Kesten and Dacheng Liu and Donald Tashkin",
year = "2011",
month = "7",
day = "1",
doi = "10.1111/j.1440-1843.2011.01982.x",
language = "English",
volume = "16",
pages = "825--835",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Efficacy of tiotropium in COPD patients from Asia

T2 - A subgroup analysis from the UPLIFT trial

AU - Fukuchi, Yoshinosuke

AU - Fernandez, Lenora

AU - Kuo, Han Pin

AU - Mahayiddin, Aziah

AU - Celli, Bartolome

AU - Decramer, Marc

AU - Kesten, Steven

AU - Liu, Dacheng

AU - Tashkin, Donald

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background and objective: Studies in respiratory diseases other than chronic obstructive pulmonary disease suggest potentially differing responses to medications among patients from different regions. We report a subgroup analysis of patients recruited to Asian centres from a previously reported 4-year COPD trial. Methods: Subgroup analysis from a randomized, double-blinded, placebo-controlled trial of tiotropium 18 μg daily in COPD. Primary end-point was rate of decline in FEV 1. Secondary end-points included spirometry at individual time points, health-related quality of life (St George's Respiratory Questionnaire), exacerbations and mortality. Results: Of 5992 patients, 362 were from Asian centres (100 from Japan). Mean age 66 years, 95% men, 13% current smokers, BMI: 21 kg/m 2; post-bronchodilator FEV 1: 44% predicted; St George's Respiratory Questionnaire total score: 44 units. No treatment effect was observed for rate of decline in FEV 1 although annual decline was less in Asian patients. Morning prebronchodilator FEV 1 and forced vital capacity improved in Asian patients (P < 0.05). Tiotropium reduced number of exacerbations (rate ratio (95% confidence interval (CI)): 0.73 (0.57-0.94)). Hazard ratios (95%CI) for exacerbations and hospitalized exacerbations (tiotropium/control) were 0.81 (0.62-1.05) and 0.85 (0.61-1.19), respectively. St George's Respiratory Questionnaire total score improvedby 1.5-6.1 units (P < 0.05 for months 18, 24, 30 and 36) with tiotropium. Fatal events occurred in 34 tiotropium (18.5%) and 42 control (23.6%) patients. Conclusions: In COPD patients from Asia, tiotropium improves lung function, improves health-related quality of life and reduces exacerbations over 4 years of treatment.

AB - Background and objective: Studies in respiratory diseases other than chronic obstructive pulmonary disease suggest potentially differing responses to medications among patients from different regions. We report a subgroup analysis of patients recruited to Asian centres from a previously reported 4-year COPD trial. Methods: Subgroup analysis from a randomized, double-blinded, placebo-controlled trial of tiotropium 18 μg daily in COPD. Primary end-point was rate of decline in FEV 1. Secondary end-points included spirometry at individual time points, health-related quality of life (St George's Respiratory Questionnaire), exacerbations and mortality. Results: Of 5992 patients, 362 were from Asian centres (100 from Japan). Mean age 66 years, 95% men, 13% current smokers, BMI: 21 kg/m 2; post-bronchodilator FEV 1: 44% predicted; St George's Respiratory Questionnaire total score: 44 units. No treatment effect was observed for rate of decline in FEV 1 although annual decline was less in Asian patients. Morning prebronchodilator FEV 1 and forced vital capacity improved in Asian patients (P < 0.05). Tiotropium reduced number of exacerbations (rate ratio (95% confidence interval (CI)): 0.73 (0.57-0.94)). Hazard ratios (95%CI) for exacerbations and hospitalized exacerbations (tiotropium/control) were 0.81 (0.62-1.05) and 0.85 (0.61-1.19), respectively. St George's Respiratory Questionnaire total score improvedby 1.5-6.1 units (P < 0.05 for months 18, 24, 30 and 36) with tiotropium. Fatal events occurred in 34 tiotropium (18.5%) and 42 control (23.6%) patients. Conclusions: In COPD patients from Asia, tiotropium improves lung function, improves health-related quality of life and reduces exacerbations over 4 years of treatment.

KW - Asia

KW - Chronic obstructive pulmonary disease

KW - Quality of life

KW - Spirometry

KW - Tiotropium

UR - http://www.scopus.com/inward/record.url?scp=79959898445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959898445&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2011.01982.x

DO - 10.1111/j.1440-1843.2011.01982.x

M3 - Article

VL - 16

SP - 825

EP - 835

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 5

ER -